IKONISYS S.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.43 EUR | -1.38% |
|
-2.72% | -8.33% |
| May. 24 | Ikonisys S.A. Announces Postponement of the Publication of its 2023 Annual Financial Report | CI |
| May. 21 | HHospitex Signs Distribution Partnership with Diagen LLC | CI |
| Sales 2023 * | 1M 1.09M | Sales 2024 * | 4.9M 5.33M | Capitalization | 15.15M 16.47M |
|---|---|---|---|---|---|
| Net income 2023 * | -1M -1.09M | Net income 2024 * | - 0 | EV / Sales 2023 * | 16.8 x |
| Net Debt 2023 * | 1.6M 1.74M | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 3.09 x |
| P/E ratio 2023 * |
-9.06
x | P/E ratio 2024 * |
72.5
x | Employees | 11 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 16.92% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.38% | ||
| 1 week | -2.72% | ||
| Current month | -2.05% | ||
| 1 month | +1.42% | ||
| 3 months | -3.38% | ||
| 6 months | -8.92% | ||
| Current year | -8.33% |
1 week
1.43
1.47
1 month
1.351.49
Current year
1.251.66
1 year
1.141.80
3 years
1.144.70
5 years
1.144.70
10 years
1.144.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 21-05-30 | |
Mario Crovetto
CEO | Chief Executive Officer | 71 | 21-06-30 |
Alessandro Mauri
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mario Mauri
CHM | Chairman | 74 | 21-05-30 |
Roberto Rettani
BRD | Director/Board Member | 71 | 21-05-30 |
Mario Crovetto
CEO | Chief Executive Officer | 71 | 21-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 1.43 | -1.38% | 432 |
| 24-06-04 | 1.45 | -0.68% | 13,295 |
| 24-06-03 | 1.46 | 0.00% | 114 |
| 24-05-31 | 1.46 | 0.00% | 294 |
| 24-05-30 | 1.46 | -0.68% | 641 |
Real-time Euronext Paris, June 05, 2024 at 03:32 am EDT
More quotes
Ikonisys S.A. is specialized in the design, manufacture and marketing of medical diagnostic equipment. The company offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. Net sales break down by source of revenue as follows:
- sales of products (65.3%): sales of Ikoniscope instruments and the related software application;
- sales of maintenance services (34.7%).
Calendar
2024-10-24
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.45
EUR
Average target price
6.3
EUR
Spread / Average Target
+334.48%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.33% | 16.49M | |
| -4.67% | 12.35B | |
| -3.76% | 8.17B | |
| +7.84% | 5.77B | |
| +31.48% | 5.65B | |
| -10.28% | 4.1B | |
| +10.72% | 2.67B | |
| -61.53% | 2.57B | |
| -7.50% | 2.31B | |
| +16.56% | 2.02B |
- Stock Market
- Equities
- ALIKO Stock
